Online gateways such as Authorize.net and NMI support research-peptide and SARMs ecommerce with tokenization and fraud tooling for one-time orders.
High-risk merchant account
Peptide Merchant Accounts for Research-Use-Only Sellers
Research peptides, SARMs, and research chemicals are declined by mainstream processors over FDA exposure and the research-use-only labeling posture. Midnight Payments underwrites that exposure up front, instead of discovering it after a freeze.
$0 monthly fees
1,600+ U.S. businesses served
15+ years in merchant services
$400M+ monthly processing volume
Shutdown pattern
Research-chemical sellers are declined on category and claim risk.
Stripe, Square, and PayPal decline research peptides, SARMs, and research chemicals categorically, and accounts that slip through are dropped once a reviewer sees the product line or a dosing claim. These compounds are not FDA-approved for human use, and FDA warning letters target sellers whose marketing crosses into human-consumption claims. A research-use review looks at the labeling posture, the disclaimers, age-gating, and the refund and dispute profile before terms are set, instead of approving on a clean signup form and terminating after the first compliance flag.
A claim-risk termination in the research-chemical category can put a peptide seller on the MATCH or TMF list, where most processors stop returning calls. see your MATCH or TMF options.
If the current processor is already expensive, unstable, or holding funds, start with a statement review. The useful comparison is what determines your rate against the costs you are already paying.
Get PricingCapability proof
Research-use-aware underwriting for peptide and SARMs ecommerce
Peptide processing turns on the compliance posture, not the billing model. The account is reviewed against the research-use-only framing, the marketing claims, and the documentation behind the product line, so the labeling and FDA-exposure questions are settled during underwriting rather than surfacing as a later account event.
Research-use-only labeling, age-gating, and the absence of human-consumption or dosing claims are reviewed up front, because that posture is what underwriting and the FDA both check.
Certificates of analysis and clear research-use disclaimers are treated as core approval documentation, not paperwork requested after the account is already at risk.
Gateways
Authorize.net / NMI / USAePay / PayTrace
Related processing capabilities for this page:
Process
How approval review works.
Apply or send a statement
Start with the merchant requisition, or use a current processing statement to anchor the review.
Underwriting reviews the actual risk
Your vertical, online payment model, chargeback profile, compliance overlay, and processing history are reviewed together.
Approval terms are compared clearly
The terms are evaluated against your current setup, with $0 monthly fees, no long-term contract, and daily ACH settlement kept visible.
Gateway setup and go live
Authorize.net, NMI, USAePay, and PayTrace options cover ecommerce, subscriptions, B2B payments, and reporting needs.
Application docs
What you will need for review.
Documents vary by risk profile, but every application starts with the business basics and then adds category-specific proof.
Standard documents
- Completed merchant requisition form
- W9
- ABA/routing number, account number, and settlement name on account
- Business license
Peptide add-ons
- Research-use-only labeling and product disclaimers
- Certificates of analysis (COAs) for the compounds sold
- Website copy showing no human-consumption, dosing, or injection claims
- Age-verification details at checkout
- 3 months of prior processing statements
FAQ
Peptide merchant account FAQ.
These answers are specific to peptide. For cross-cutting approval, pricing, reserve, and gateway questions, see the full FAQ.
Can you process research peptides, SARMs, and research chemicals?
Yes. Research peptides, SARMs, and research chemicals sold for research use only can be reviewed when the labeling, certificates of analysis, and marketing copy support that posture. Underwriting looks at the compliance framing and dispute profile rather than declining the category on sight the way mainstream processors do.
How is a peptide account different from a nutraceutical or supplement account?
A supplement account covers ingestible dietary products marketed for human consumption under DSHEA, often on subscriptions. A peptide account covers research compounds sold for research use only, with no human-use claims and an FDA-drug gray area. The underwriting and compliance review are different, so the two are kept on separate accounts.
Will human-consumption or dosing claims affect approval?
Yes, directly. Marketing that describes dosing, injection, or human use moves the product from research use into unapproved-drug territory, which is the exact line FDA warning letters target. Keeping the site, labels, and disclaimers strictly research-use-only is part of staying approved, and that copy is reviewed during underwriting.
Do you require certificates of analysis?
Certificates of analysis for the compounds sold are expected during review. They show product identity and purity and support the research-use framing, which helps underwriting separate a documented research-supply business from an unlabeled research-chemical seller making health claims.
Can I get approved after Stripe or PayPal shut down my peptide store?
Yes. A prior shutdown is common for research-peptide sellers because mainstream processors decline the category. Underwriting reviews your transaction profile, product line, labeling, and compliance materials instead of repeating the categorical decline, and a clean research-use posture strengthens the application.
Does FDA exposure mean a peptide account cannot be approved?
Not automatically, but a merchant account is never a judgment that your model is legal. These compounds are not FDA-approved for human use, and a research-use-only label does not by itself make a sale compliant; the FDA can still treat research chemicals sold to consumers as unapproved drugs. Underwriting prices the payment and dispute risk, not the legality of your business, which is on you and your counsel. A clean research-use posture with proper labeling and COAs is what keeps the payment side reviewable rather than an automatic decline.
Are there monthly fees?
No. Midnight Payments uses a $0 monthly fee posture, with the cost handled through processing fees.
How fast is settlement?
Settlement is handled through daily ACH funding once the account is live.
Get reviewed
Get research peptides and SARMs reviewed by underwriting that reads the research-use posture before the first transaction.
Share your vertical, monthly volume, current processor status, and any recent statements. Midnight Payments will route the review toward a merchant account fit for the actual risk.